Rifampicin PLGA nanospheres are formulated with a specific goal in order to decrease the dose, adverse effects and to enhance targeted drug delivery. Rifampicin nanospheres were prepared and evaluated by emulsion solvent evaporation method. In vivo bio distribution studies reveal that there was a long term accumulation of rifampicin nanospheres in the lungs over other organs. The increase in Cmax values confirmed that inhalable PLGA nanospheres are suitable for targeting and providing sustained release of antitubercular drugs to lungs. So inhalation is a selected administration route of Rifampicin PLGA nanospheres. The in vivo screening of M. tuberculosis showed good activity as well as its activity against multidrug-resistant M. tuberculosis and against M. tuberculosis isolates in a potentially latent state, makes Rifampicin PLGA nanospheres as an attractive drug dosage form for the therapy of tuberculosis. It can be concluded that there is a significant potential for effective oral delivery as well as nasal delivery of the Nanospheres for the treatment of tuberculosis.
Comments: 8 Pages. OK
[v1] 2019-05-19 02:42:54
Unique-IP document downloads: 1 times
Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.
Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.